Innovation Pharmaceuticals Inc (IPIX)

[Chronic]

Farrell, one big difference when comparing both trials' reduction of incidence:

GC4419 reported a 34% reduction of SOM in their "Intent-to-treat" population. That means they are not cutting out any patients from their results. Everyone who participated in the trial is counted.

Brilacidin reported a 39% reduction in their "per protocol" population and 28% reduction on their "modified-intent-to-treat" population. No word at all from IPIX what the numbers are for the "intent-to-treat" population, but you can probably assume it is a lot lower than 28% or they would have reported them.